Indoco's AnaCipher CRO clears USFDA inspection with Zero 483s

Indoco Remedies Ltd. announced today that its Clinical Research Organisation, AnaCipher, located in Hyderabad, was inspected by the United States Food and Drug Administration from September 12 to September 16, 2022. The clinical phase of inspection covered three BA/BE studies submitted by clients to the USFDA and was successfully concluded with zero 483s.

"This is the seventh successive USFDA inspection with ZERO 483s for AnaCipher CRO. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services to our clients.", said Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited.

Source : Equity Bulls

Keywords

IndocoRemedies CRO AnaCipher Hyderabad USFDA Inspection Zero483s